Regeneron’s clinical trials are at the core of this mission. Regeneron is grateful to all clinical trial participants — ...

with manageable hyperkalemia risks through protocolized monitoring and dose adjustments, maintaining clinical benefits even ...

While exercise is generally beneficial for a person's overall health, physical activities may increase the risk of adverse cardiovascular ... support device performance or clinical, or safety outcomes ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

While exercise is generally beneficial for a person's overall health, physical activities may increase the risk of adverse ...

An immune-cell therapy shrank children's brain tumors, restored neurologic function and—for one participant in a Stanford ...

Study links hallucinogen use to higher schizophrenia risk, highlighting the need for caution and informed decisions on ...

Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patientsBoth artificial ...

Real-world data on GLP-1R agonists’ safety in heart failure and CKD patients was investigated using the TriNetX Research ...

Real progress in health inequities requires meeting communities where they are and addressing the root causes of medical ...

CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight ...

Nothing about pregnancy diminishes an individual’s decision-making capacity or obviates their right to make decisions related ...